Blueprint
 
 
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION

 
Washington D.C. 20549
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of

 
the Securities Exchange Act of 1934
 
 
 
For period ending 15 January 2018 
 
GlaxoSmithKline plc
 
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
 
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
 
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
 
 
Form 20-F x     Form 40-F

 
 
 
--

 
 
 
Indicate by check mark whether the registrant by furnishing the
 
information contained in this Form is also thereby furnishing the
 
information to the Commission pursuant to Rule 12g3-2(b) under the
 
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
GlaxoSmithKline plc
 
(the 'Company')
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of
the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.3440
473.274
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
e)
Date of the transaction
2018-01-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each
('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.3440
82.400
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2018-01-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Debruyne
b)
Position/status
President, Global Vaccines
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.3440
851.563
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
e)
Date of the transaction
2018-01-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each
('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.3440
919.518
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
e)
Date of the transaction
2018-01-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.3440
1552.174
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
e)
Date of the transaction
2018-01-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, HR
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.3440
599.748
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
e)
Date of the transaction
2018-01-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.3440
728.198
d)
Aggregated
information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
e)
Date of the transaction
2018-01-11
f)
Place of the transaction
 
London Stock Exchange (XLON
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.3440
2918.217
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
e)
Date of the transaction
2018-01-11
f)
Place of the transaction
 
London Stock Exchange (XLON
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs K Thomson
b)
Position/status
PCA of Mr P C Thomson
(President, Global Affairs)
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.3440
137.540
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
e)
Date of the transaction
2018-01-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
SIGNATURES
 
 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: January 15, 2018 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc